Review



pancreatic cancer cell lines miapaca 2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC pancreatic cancer cell lines miapaca 2
    Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.
    Pancreatic Cancer Cell Lines Miapaca 2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4593 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/MIA+PaCa-2/pmc13763989-277-1-6
    Average 99 stars, based on 4593 article reviews
    pancreatic cancer cell lines miapaca 2 - by Bioz Stars, 2026-11
    99/100 stars

    Images

    1) Product Images from "Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells"

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms272110013

    Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.
    Figure Legend Snippet: Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.

    Techniques Used: Activity Assay, Hexosaminidase Assay, Positive Control

    Dose- and time-dependent antiproliferative activity of 4b (A4, panel ( A )), 4a (A5, panel ( B )), and 3a (A19, panel ( C )) against MiaPaCa-2 and S2-007 PDAC cells. Cells were treated with 0–2.5 µM of each compound for 24–72 h, and proliferation was measured by hexosaminidase assay and expressed as a percentage of untreated control. Data are presented as mean ± SD of three independent experiments.
    Figure Legend Snippet: Dose- and time-dependent antiproliferative activity of 4b (A4, panel ( A )), 4a (A5, panel ( B )), and 3a (A19, panel ( C )) against MiaPaCa-2 and S2-007 PDAC cells. Cells were treated with 0–2.5 µM of each compound for 24–72 h, and proliferation was measured by hexosaminidase assay and expressed as a percentage of untreated control. Data are presented as mean ± SD of three independent experiments.

    Techniques Used: Activity Assay, Hexosaminidase Assay, Control

    Time-dependent antiproliferative activity of 3a against KRAS-mutant PDAC cells  (MiaPaCa-2,  S2-007, Panc-1) and the human leukemia cell lines Jurkat and THP-1 cells, expressed as IC 50 (µM) 1 , as determined by a hexosaminidase assay (PDAC lines) or CCK-8 assay (Jurkat and THP-1 cells).
    Figure Legend Snippet: Time-dependent antiproliferative activity of 3a against KRAS-mutant PDAC cells (MiaPaCa-2, S2-007, Panc-1) and the human leukemia cell lines Jurkat and THP-1 cells, expressed as IC 50 (µM) 1 , as determined by a hexosaminidase assay (PDAC lines) or CCK-8 assay (Jurkat and THP-1 cells).

    Techniques Used: Activity Assay, Hexosaminidase Assay, CCK-8 Assay

    Compound 3a induces apoptosis in PDAC cells. ( A ) Representative Annexin V-FITC/PI flow cytometry dot plots of MiaPaCa-2 (top) and Panc-1 (bottom) cells treated with vehicle (Ctrl) or 3a (A19) at IC 50 (260 nM MiaPaCa-2; 560 nM Panc-1) for 48 h. Quadrants show live (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) cells. ( B ) Quantification of the percentage of cells in each quadrant for MiaPaCa-2 (left) and Panc-1 (right) cells. Dots represent independent experiments ( n = 3); p -values were determined by an unpaired two-tailed Student t -test for each quadrant. ( C ) Caspase-3/7 activity in MiaPaCa-2 and S2-007 cells after 48 h of treatment with 3a (A19) at ½ IC 50 (130 nM MiaPaCa-2; 110 nM S2-007) or IC 50 (260 nM MiaPaCa-2; 220 nM S2-007), expressed relative to untreated control (Ctrl, 0 nM). Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus control. ( D ) Effect of 3a (A19) on apoptosis-related protein expression in MiaPaCa-2 and S2-007 cells. Western blots show reduced Bcl-2, Bcl-Xl, and cyclin D1 levels in cells treated with 3a at its IC 50 concentration (+) for 24 h or 48 h compared with vehicle (−), while Bax expression remained unchanged. GAPDH was used as a loading control. Densitometric quantification from three independent experiments is shown in .
    Figure Legend Snippet: Compound 3a induces apoptosis in PDAC cells. ( A ) Representative Annexin V-FITC/PI flow cytometry dot plots of MiaPaCa-2 (top) and Panc-1 (bottom) cells treated with vehicle (Ctrl) or 3a (A19) at IC 50 (260 nM MiaPaCa-2; 560 nM Panc-1) for 48 h. Quadrants show live (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) cells. ( B ) Quantification of the percentage of cells in each quadrant for MiaPaCa-2 (left) and Panc-1 (right) cells. Dots represent independent experiments ( n = 3); p -values were determined by an unpaired two-tailed Student t -test for each quadrant. ( C ) Caspase-3/7 activity in MiaPaCa-2 and S2-007 cells after 48 h of treatment with 3a (A19) at ½ IC 50 (130 nM MiaPaCa-2; 110 nM S2-007) or IC 50 (260 nM MiaPaCa-2; 220 nM S2-007), expressed relative to untreated control (Ctrl, 0 nM). Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus control. ( D ) Effect of 3a (A19) on apoptosis-related protein expression in MiaPaCa-2 and S2-007 cells. Western blots show reduced Bcl-2, Bcl-Xl, and cyclin D1 levels in cells treated with 3a at its IC 50 concentration (+) for 24 h or 48 h compared with vehicle (−), while Bax expression remained unchanged. GAPDH was used as a loading control. Densitometric quantification from three independent experiments is shown in .

    Techniques Used: Flow Cytometry, Two Tailed Test, Activity Assay, Control, Expressing, Western Blot, Concentration Assay

    Compound 3a inhibits primary and secondary spheroid formation in PDAC cells. ( A ) Representative brightfield images of primary MiaPaCa-2 (top) and S2-007 (bottom) spheroids after 7 days in the absence (Ctrl) or presence of 3a (A19) at its IC 50 concentration. ( B ) Quantification of primary spheroid number per well for MiaPaCa-2 and S2-007 cells. ( C ) Representative brightfield images of secondary MiaPaCa-2 (top) and S2-007 (bottom) spheroids formed after primary spheroids from control and 3a -treated wells were dissociated and re-plated in drug-free spheroid medium for 5 days. ( D ) Quantification of secondary spheroid number per well for MiaPaCa-2 and S2-007 cells. Data in ( B ) and ( D ) are shown as box-and-whisker plots (median, interquartile range, and min–max) with individual data points; p -values were determined by unpaired two-tailed Student’s t -test. Dots represent individual wells ( n = 9 per group, 3 wells from each of 3 independent experiments).
    Figure Legend Snippet: Compound 3a inhibits primary and secondary spheroid formation in PDAC cells. ( A ) Representative brightfield images of primary MiaPaCa-2 (top) and S2-007 (bottom) spheroids after 7 days in the absence (Ctrl) or presence of 3a (A19) at its IC 50 concentration. ( B ) Quantification of primary spheroid number per well for MiaPaCa-2 and S2-007 cells. ( C ) Representative brightfield images of secondary MiaPaCa-2 (top) and S2-007 (bottom) spheroids formed after primary spheroids from control and 3a -treated wells were dissociated and re-plated in drug-free spheroid medium for 5 days. ( D ) Quantification of secondary spheroid number per well for MiaPaCa-2 and S2-007 cells. Data in ( B ) and ( D ) are shown as box-and-whisker plots (median, interquartile range, and min–max) with individual data points; p -values were determined by unpaired two-tailed Student’s t -test. Dots represent individual wells ( n = 9 per group, 3 wells from each of 3 independent experiments).

    Techniques Used: Brightfield, Spheroids, Concentration Assay, Control, Whisker Assay, Two Tailed Test

    Compound 3a inhibited colony formation in PDAC cells. ( A ) Representative crystal-violet-stained wells of MiaPaCa-2 (top) and S2-007 (bottom) cells 10–12 days after a 48 h treatment with 0, ½ IC 50 (0.5X), or IC 50 (1X) concentrations of 3a (A19) followed by drug-free recovery. ( B ) Quantification of colony number for MiaPaCa-2 and S2-007 cells under the same conditions. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus untreated control.
    Figure Legend Snippet: Compound 3a inhibited colony formation in PDAC cells. ( A ) Representative crystal-violet-stained wells of MiaPaCa-2 (top) and S2-007 (bottom) cells 10–12 days after a 48 h treatment with 0, ½ IC 50 (0.5X), or IC 50 (1X) concentrations of 3a (A19) followed by drug-free recovery. ( B ) Quantification of colony number for MiaPaCa-2 and S2-007 cells under the same conditions. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus untreated control.

    Techniques Used: Colony Assay, Staining, Control

    Compound 3a inhibited STAT3 phosphorylation (Tyr705) in PDAC cells. ( A ) Western blots of p-STAT3 in MiaPaCa-2 and S2-007 cells treated with vehicle or 3a (A19) at its IC 50 concentration for 24 h or 48 h; GAPDH served as a loading control. ( B ) Densitometric quantification of p-STAT3 (Tyr705) normalized to total STAT3, relative to the respective untreated control, for each cell line and time point. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by an unpaired two-tailed Student t -test versus the time-matched vehicle control.
    Figure Legend Snippet: Compound 3a inhibited STAT3 phosphorylation (Tyr705) in PDAC cells. ( A ) Western blots of p-STAT3 in MiaPaCa-2 and S2-007 cells treated with vehicle or 3a (A19) at its IC 50 concentration for 24 h or 48 h; GAPDH served as a loading control. ( B ) Densitometric quantification of p-STAT3 (Tyr705) normalized to total STAT3, relative to the respective untreated control, for each cell line and time point. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by an unpaired two-tailed Student t -test versus the time-matched vehicle control.

    Techniques Used: Phospho-proteomics, Western Blot, Concentration Assay, Control, Two Tailed Test

    Cellular thermal shift assay (CETSA) showing that 3a binds STAT3. ( A ) Representative Western blots of soluble STAT3 in MiaPaCa-2 cell lysates incubated with vehicle (DMSO) or 3a (A19) at 20 µM for 4 h, then heated at the indicated temperatures (44–68 °C) for 3 min. ( B ) Melting curves of soluble STAT3, quantified by densitometry and normalized to the 44 °C sample of each group. Curves were fitted by nonlinear (Boltzmann sigmoidal) regression. Derivative 3a raised the melting temperature (T m ) of STAT3 from 56.3 °C (vehicle) to 62.6 °C (ΔT m = +6.3 °C), indicating thermal stabilization of STAT3 by direct ligand binding. Data are presented as mean ± SD ( n = 3). p -values above individual temperatures compare vehicle with 3a at each temperature; the overall curve comparison (extra sum-of-squares F-test) gave p < 0.0001.
    Figure Legend Snippet: Cellular thermal shift assay (CETSA) showing that 3a binds STAT3. ( A ) Representative Western blots of soluble STAT3 in MiaPaCa-2 cell lysates incubated with vehicle (DMSO) or 3a (A19) at 20 µM for 4 h, then heated at the indicated temperatures (44–68 °C) for 3 min. ( B ) Melting curves of soluble STAT3, quantified by densitometry and normalized to the 44 °C sample of each group. Curves were fitted by nonlinear (Boltzmann sigmoidal) regression. Derivative 3a raised the melting temperature (T m ) of STAT3 from 56.3 °C (vehicle) to 62.6 °C (ΔT m = +6.3 °C), indicating thermal stabilization of STAT3 by direct ligand binding. Data are presented as mean ± SD ( n = 3). p -values above individual temperatures compare vehicle with 3a at each temperature; the overall curve comparison (extra sum-of-squares F-test) gave p < 0.0001.

    Techniques Used: Thermal Shift Assay, Western Blot, Incubation, Ligand Binding Assay, Comparison

    Related Articles

    Incubator:

    Article Title: Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring
    Article Snippet: .. MiaPaCa-2 cells (ATCC No. CRL-1420) were grown at 37 °C (humidified incubator with 5% CO 2 ) in Dulbecco's Modified Eagle's Medium (DMEM) containing fetal bovine serum (FBS) in a final concentration of 10% and horse serum in a final concentration of 2.5%. ..

    Modification:

    Article Title: Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring
    Article Snippet: .. MiaPaCa-2 cells (ATCC No. CRL-1420) were grown at 37 °C (humidified incubator with 5% CO 2 ) in Dulbecco's Modified Eagle's Medium (DMEM) containing fetal bovine serum (FBS) in a final concentration of 10% and horse serum in a final concentration of 2.5%. ..

    Article Title: Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance
    Article Snippet: .. MiaPaCa-2 cells were purchased from the ATCC and cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% antibiotic–antimycotic. ..

    Concentration Assay:

    Article Title: Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring
    Article Snippet: .. MiaPaCa-2 cells (ATCC No. CRL-1420) were grown at 37 °C (humidified incubator with 5% CO 2 ) in Dulbecco's Modified Eagle's Medium (DMEM) containing fetal bovine serum (FBS) in a final concentration of 10% and horse serum in a final concentration of 2.5%. ..

    Cell Culture:

    Article Title: Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer
    Article Snippet: .. MiaPaCa-2 cells (ATCC), cfPac-1 (ATCC), p53 2.1.1-pMSCV-FLuc (a gift from Dr. E. Collisson, University of California, San Francisco, CA) and PI34 (a gift from Dr. A. D. Rhim, M. D. Anderson Cancer Center, Houston, TX) were cultured in DMEM supplemented with 10% FBS, and antibiotics (100 μg/ml streptomycin and 100 U/ml penicillin). ..

    Article Title: Targeting tumor antioxidant pathways with novel GSTP1/M2 inhibitors for cancer treatment
    Article Snippet: .. MDA-MB-231 cells (ATCC) grown in DMEM supplemented with 10% FBS and penicillin-streptomycin (50 μg/mL), MiaPaCa-2 cells (ATCC) grown in DMEM supplemented with 10% FBS, horse serum (2.5%), 4T1 cells (ATCC) and 67NR (University of Minnesota Duluth, Dr. Jon Holy) cultured in RPMI-1640 supplemented with 10% FBS and penicillin streptomycin (50 μg/mL). ..

    Article Title: Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance
    Article Snippet: .. MiaPaCa-2 cells were purchased from the ATCC and cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% antibiotic–antimycotic. ..

    Multiple Displacement Amplification:

    Article Title: Targeting tumor antioxidant pathways with novel GSTP1/M2 inhibitors for cancer treatment
    Article Snippet: .. MDA-MB-231 cells (ATCC) grown in DMEM supplemented with 10% FBS and penicillin-streptomycin (50 μg/mL), MiaPaCa-2 cells (ATCC) grown in DMEM supplemented with 10% FBS, horse serum (2.5%), 4T1 cells (ATCC) and 67NR (University of Minnesota Duluth, Dr. Jon Holy) cultured in RPMI-1640 supplemented with 10% FBS and penicillin streptomycin (50 μg/mL). ..



    Similar Products

    99
    ATCC pancreatic cancer cell lines miapaca 2
    Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.
    Pancreatic Cancer Cell Lines Miapaca 2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/MIA+PaCa-2/pmc13763989-277-1-6
    Average 99 stars, based on 1 article reviews
    pancreatic cancer cell lines miapaca 2 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human cell lines miapaca 2
    Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.
    Human Cell Lines Miapaca 2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/MIA+PaCa-2/pm42284146-234-2-6
    Average 99 stars, based on 1 article reviews
    human cell lines miapaca 2 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    86
    Jackson Laboratory miapaca 2 cells
    ( a, b ) DHHC7 promotes pERK and 2-D cell growth of pancreatic cancer cells. ZDHHC7 was knockdown using siRNA in four mutant KRAS-driven pancreatic cancer cell lines (AsPC1, <t>MiaPaca-2,</t> PANC0327 and Tu8988s) ( a ) and one non-KRAS driven pancreatic cancer cell line (BxPC3) ( b ). pERK was measured using western blot and 2-D cell growth was measured using Cell Titer Glow after 48-72 hrs. ( c-d ) ZDHHC7 knockout affects pERK, 2-D cell growth, KRAS4A S-palmitoylation in MiaPaca-2 cell line. ZDHHC7 was CRISPR knockout and pERK levels ( c ) were detected using western blot and 2D cell growth was measured after 72 hrs. The endogenous S-acylation level of KRAS4A was detected using ABE ( d ). ( e ) ZDHHC7 was CRISPR knockout in AsPC1 cell line and pERK levels were detected using western blot. ( f-h ) ZDHHC7 knockout suppresses MiaPaca-2 xenograft tumor growth. Pancreatic cancer xerograph was performed using MiaPaca-2 cells with control or ZDHHC7 CRISPR knockout. The tumor volume was measured and quantified (f). The mice were dissected, and the final tumors were shown ( g ) and the tumor weights were quantified ( h ). ( i-k ) ZDHHC7 knockout suppresses AsPC1 xenograft tumor growth. ZDHHC7 CRISPR knockout was performed in AsPC1 cell line and similar xenograft experiment was performed. Tumor volume (i), tumors (j), tumor weight (k) are shown. Quantification data are shown as mean ± SD. ns, not significant. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Miapaca 2 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/2+cells+miapaca/bio_rxiv__64898__2026__03__31__715686-238-6-47
    Average 86 stars, based on 1 article reviews
    miapaca 2 cells - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    97
    ATCC miapaca 2 cells
    Cytotoxicity and Cell adsorption property of PVA-U varying G.D. (a) IC 50 values <t>of</t> <t>MIAPaCa-2</t> cells treated with UDCA, PVA-U3, PVA-U15, and PVA-U25 for 24 h incubation at pH 7.4 and pH 6.5 (n = 3). (b) Cell viability of MIAPaCa-2 cells treated with 10 μg mL −1 PVA-U15 at pH 7.4 and pH 6.5 for 0, 4, 12, and 24 h incubation (n = 3). (c) Confocal images of MIAPaCa-2 cells treated with Cell tracker deep red and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 7.4 and pH 6.5 for 12 h incubation. Cell tracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 100 μm and 50 μm, respectively. Quantification of intracellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 24 h at pH 7.4 (d) and pH 6.5 (e) (n = 11). Quantification of pericellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 4 h at pH 7.4 (f) and pH 6.5 (g) (n = 11). (h) Confocal images of MIAPaCa-2 cells treated with lysotracker and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 6.5 for 4 h incubation. Lysotracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 50 μm and 10 μm, respectively. Statistical analysis was performed using unpaired two-tailed Student's t -test. Data are presented as mean ± S.D. ( N.S. : no significant difference, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001).
    Miapaca 2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/MIA+PaCa-2/pmc12857268-267-0-11
    Average 97 stars, based on 1 article reviews
    miapaca 2 cells - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    99
    Dojindo Labs miapaca 2 cells
    Cytotoxicity and Cell adsorption property of PVA-U varying G.D. (a) IC 50 values <t>of</t> <t>MIAPaCa-2</t> cells treated with UDCA, PVA-U3, PVA-U15, and PVA-U25 for 24 h incubation at pH 7.4 and pH 6.5 (n = 3). (b) Cell viability of MIAPaCa-2 cells treated with 10 μg mL −1 PVA-U15 at pH 7.4 and pH 6.5 for 0, 4, 12, and 24 h incubation (n = 3). (c) Confocal images of MIAPaCa-2 cells treated with Cell tracker deep red and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 7.4 and pH 6.5 for 12 h incubation. Cell tracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 100 μm and 50 μm, respectively. Quantification of intracellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 24 h at pH 7.4 (d) and pH 6.5 (e) (n = 11). Quantification of pericellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 4 h at pH 7.4 (f) and pH 6.5 (g) (n = 11). (h) Confocal images of MIAPaCa-2 cells treated with lysotracker and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 6.5 for 4 h incubation. Lysotracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 50 μm and 10 μm, respectively. Statistical analysis was performed using unpaired two-tailed Student's t -test. Data are presented as mean ± S.D. ( N.S. : no significant difference, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001).
    Miapaca 2 Cells, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/Cell+Counting+Kit-8/pm41709860-332-5-15
    Average 99 stars, based on 1 article reviews
    miapaca 2 cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Beyotime miapaca 2 cells
    TNFAIP8 is enriched in insulin‐stimulated PDAC exosomes and promotes CAF activation. (A) Heatmap of differentially expressed proteins in exosomes from insulin‐treated versus control MIA PaCa‐2 cells. (B) KEGG pathway enrichment analysis of upregulated exosomal proteins. (C) Expression of TNFAIP8 based on normalized TCGA‐PAAD data. (D) Forest plot summarizing Cox regression analyses linking TNFAIP8 expression to survival outcomes across multiple datasets (TCGA, GSE79668 , GSE28735 , GSE57495 , ICGC, GSE62452 , GSE85916 , MTAB_6134, GSE71729 , GSE21501 ). (E) Kaplan‐Meier survival analyses for TNFAIP8 expression in PDAC cohorts. (TCGA, GSE85916 , GSE57495 ). Data were analyzed using the BEST (Biomarker Evaluation & Survival Tool) database (D, E). (F) IF images showing uptake of exosomes by CAFs. Scale bars, 20 µm. (G) ELISA quantification of TNFAIP8 levels in cell supernatants and exosomes from indicated PDAC cells <t>(MIAPaCa‐2,</t> PANC1) ( n = 3 biological replicates). (H) ELISA measurement of TNFAIP8 concentration in CM and exosome fractions collected from MIA PaCa‐2 cells under control or insulin treatment, with sh‐NC or sh‐TNFAIP8 expression. ( n = 3 biological replicates). (I) CCK‐8 assay for CAF viability after exosome or rTNFAIP8 treatment ( n = 3 biological replicates). (J) Representative EdU staining images and quantification of CAF proliferation under indicated treatments ( n = 5 biological replicates). Scale bars, 50 µm. (K) 3D fluorescence intensity plots showing α‐SMA and COL1A1 expression in CAFs under indicated treatments. (L) Multiplex IF staining of human PDAC tissues showing co‐localization of TNFAIP8 with α‐SMA and CK19, Samples include normal pancreas, Tumor‐INS‐Low, and Tumor‐INS‐High groups. The Tumor‐INS‐High group consists of PDAC patients with elevated insulin levels in both tumor tissue and matched fasting serum, whereas Tumor‐INS‐Low represents patients with lower insulin levels. (TMA, n = 60; Tumor‐INS‐High, n = 15; Tumor‐INS‐Low, n = 45). Scale bars: 500 and 50 µm. (M) Correlation analyses between TNFAIP8 expression and stromal markers (ACTA2 and COL1A1) in TCGA PDAC samples. Statistical comparisons between two groups were performed using a two‐tailed unpaired Student's t ‐tests (C). Data in (G, H, I, J) are shown as mean ± SD, analyzed by one‐way ANOVA with Tukey's test; Significance thresholds: ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Miapaca 2 Cells, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/Cell+Counting+Kit-8/pmc13116271-309-5-21
    Average 99 stars, based on 1 article reviews
    miapaca 2 cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC miapaca 2 crl 1420 cell lines
    Glycolytic Profiling and LDHA Inhibition Reveal Differential Sensitivity Across PDAC Cell Lines. a Heatmap of glycolytic signature expression, reported as normalized transcript per million (nTPM) across five PDAC cell lines from Human Protein Atlas. b Western blot analysis of LDHA expression in PL45, SW1990, PANC-1, <t>MIAPaCa-2,</t> and HPAF-II cells. c Glycolytic activity in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells after LDHA-i treatment, measured as extracellular acidification rate (ECAR). Each dot represents a biological replicate ( n = 6 per group). Data are represented as mean ± SD. Statistical analysis performed with a paired t -test. d Viability assay in MIAPaCa-2 (green), PANC-1 (blue), PL45 (purple), HPAF-II (red), and HPDE6c7 (brown) cells upon LDHA-i treatment at 24 and 48 h. Boxplots display IC50 values for each time point across cell lines, with statistical significance assessed by paired t -test ( n = 2 per group). On the right, GR50 and GRmax values represent drug potency and efficacy, respectively
    Miapaca 2 Crl 1420 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/miapaca+2+cells/MIA+PaCa-2/pmc12816621-384-10-17
    Average 99 stars, based on 1 article reviews
    miapaca 2 crl 1420 cell lines - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    Image Search Results


    Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Activity Assay, Hexosaminidase Assay, Positive Control

    Dose- and time-dependent antiproliferative activity of 4b (A4, panel ( A )), 4a (A5, panel ( B )), and 3a (A19, panel ( C )) against MiaPaCa-2 and S2-007 PDAC cells. Cells were treated with 0–2.5 µM of each compound for 24–72 h, and proliferation was measured by hexosaminidase assay and expressed as a percentage of untreated control. Data are presented as mean ± SD of three independent experiments.

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Dose- and time-dependent antiproliferative activity of 4b (A4, panel ( A )), 4a (A5, panel ( B )), and 3a (A19, panel ( C )) against MiaPaCa-2 and S2-007 PDAC cells. Cells were treated with 0–2.5 µM of each compound for 24–72 h, and proliferation was measured by hexosaminidase assay and expressed as a percentage of untreated control. Data are presented as mean ± SD of three independent experiments.

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Activity Assay, Hexosaminidase Assay, Control

    Time-dependent antiproliferative activity of 3a against KRAS-mutant PDAC cells  (MiaPaCa-2,  S2-007, Panc-1) and the human leukemia cell lines Jurkat and THP-1 cells, expressed as IC 50 (µM) 1 , as determined by a hexosaminidase assay (PDAC lines) or CCK-8 assay (Jurkat and THP-1 cells).

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Time-dependent antiproliferative activity of 3a against KRAS-mutant PDAC cells (MiaPaCa-2, S2-007, Panc-1) and the human leukemia cell lines Jurkat and THP-1 cells, expressed as IC 50 (µM) 1 , as determined by a hexosaminidase assay (PDAC lines) or CCK-8 assay (Jurkat and THP-1 cells).

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Activity Assay, Hexosaminidase Assay, CCK-8 Assay

    Compound 3a induces apoptosis in PDAC cells. ( A ) Representative Annexin V-FITC/PI flow cytometry dot plots of MiaPaCa-2 (top) and Panc-1 (bottom) cells treated with vehicle (Ctrl) or 3a (A19) at IC 50 (260 nM MiaPaCa-2; 560 nM Panc-1) for 48 h. Quadrants show live (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) cells. ( B ) Quantification of the percentage of cells in each quadrant for MiaPaCa-2 (left) and Panc-1 (right) cells. Dots represent independent experiments ( n = 3); p -values were determined by an unpaired two-tailed Student t -test for each quadrant. ( C ) Caspase-3/7 activity in MiaPaCa-2 and S2-007 cells after 48 h of treatment with 3a (A19) at ½ IC 50 (130 nM MiaPaCa-2; 110 nM S2-007) or IC 50 (260 nM MiaPaCa-2; 220 nM S2-007), expressed relative to untreated control (Ctrl, 0 nM). Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus control. ( D ) Effect of 3a (A19) on apoptosis-related protein expression in MiaPaCa-2 and S2-007 cells. Western blots show reduced Bcl-2, Bcl-Xl, and cyclin D1 levels in cells treated with 3a at its IC 50 concentration (+) for 24 h or 48 h compared with vehicle (−), while Bax expression remained unchanged. GAPDH was used as a loading control. Densitometric quantification from three independent experiments is shown in .

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Compound 3a induces apoptosis in PDAC cells. ( A ) Representative Annexin V-FITC/PI flow cytometry dot plots of MiaPaCa-2 (top) and Panc-1 (bottom) cells treated with vehicle (Ctrl) or 3a (A19) at IC 50 (260 nM MiaPaCa-2; 560 nM Panc-1) for 48 h. Quadrants show live (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) cells. ( B ) Quantification of the percentage of cells in each quadrant for MiaPaCa-2 (left) and Panc-1 (right) cells. Dots represent independent experiments ( n = 3); p -values were determined by an unpaired two-tailed Student t -test for each quadrant. ( C ) Caspase-3/7 activity in MiaPaCa-2 and S2-007 cells after 48 h of treatment with 3a (A19) at ½ IC 50 (130 nM MiaPaCa-2; 110 nM S2-007) or IC 50 (260 nM MiaPaCa-2; 220 nM S2-007), expressed relative to untreated control (Ctrl, 0 nM). Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus control. ( D ) Effect of 3a (A19) on apoptosis-related protein expression in MiaPaCa-2 and S2-007 cells. Western blots show reduced Bcl-2, Bcl-Xl, and cyclin D1 levels in cells treated with 3a at its IC 50 concentration (+) for 24 h or 48 h compared with vehicle (−), while Bax expression remained unchanged. GAPDH was used as a loading control. Densitometric quantification from three independent experiments is shown in .

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Flow Cytometry, Two Tailed Test, Activity Assay, Control, Expressing, Western Blot, Concentration Assay

    Compound 3a inhibits primary and secondary spheroid formation in PDAC cells. ( A ) Representative brightfield images of primary MiaPaCa-2 (top) and S2-007 (bottom) spheroids after 7 days in the absence (Ctrl) or presence of 3a (A19) at its IC 50 concentration. ( B ) Quantification of primary spheroid number per well for MiaPaCa-2 and S2-007 cells. ( C ) Representative brightfield images of secondary MiaPaCa-2 (top) and S2-007 (bottom) spheroids formed after primary spheroids from control and 3a -treated wells were dissociated and re-plated in drug-free spheroid medium for 5 days. ( D ) Quantification of secondary spheroid number per well for MiaPaCa-2 and S2-007 cells. Data in ( B ) and ( D ) are shown as box-and-whisker plots (median, interquartile range, and min–max) with individual data points; p -values were determined by unpaired two-tailed Student’s t -test. Dots represent individual wells ( n = 9 per group, 3 wells from each of 3 independent experiments).

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Compound 3a inhibits primary and secondary spheroid formation in PDAC cells. ( A ) Representative brightfield images of primary MiaPaCa-2 (top) and S2-007 (bottom) spheroids after 7 days in the absence (Ctrl) or presence of 3a (A19) at its IC 50 concentration. ( B ) Quantification of primary spheroid number per well for MiaPaCa-2 and S2-007 cells. ( C ) Representative brightfield images of secondary MiaPaCa-2 (top) and S2-007 (bottom) spheroids formed after primary spheroids from control and 3a -treated wells were dissociated and re-plated in drug-free spheroid medium for 5 days. ( D ) Quantification of secondary spheroid number per well for MiaPaCa-2 and S2-007 cells. Data in ( B ) and ( D ) are shown as box-and-whisker plots (median, interquartile range, and min–max) with individual data points; p -values were determined by unpaired two-tailed Student’s t -test. Dots represent individual wells ( n = 9 per group, 3 wells from each of 3 independent experiments).

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Brightfield, Spheroids, Concentration Assay, Control, Whisker Assay, Two Tailed Test

    Compound 3a inhibited colony formation in PDAC cells. ( A ) Representative crystal-violet-stained wells of MiaPaCa-2 (top) and S2-007 (bottom) cells 10–12 days after a 48 h treatment with 0, ½ IC 50 (0.5X), or IC 50 (1X) concentrations of 3a (A19) followed by drug-free recovery. ( B ) Quantification of colony number for MiaPaCa-2 and S2-007 cells under the same conditions. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus untreated control.

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Compound 3a inhibited colony formation in PDAC cells. ( A ) Representative crystal-violet-stained wells of MiaPaCa-2 (top) and S2-007 (bottom) cells 10–12 days after a 48 h treatment with 0, ½ IC 50 (0.5X), or IC 50 (1X) concentrations of 3a (A19) followed by drug-free recovery. ( B ) Quantification of colony number for MiaPaCa-2 and S2-007 cells under the same conditions. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus untreated control.

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Colony Assay, Staining, Control

    Compound 3a inhibited STAT3 phosphorylation (Tyr705) in PDAC cells. ( A ) Western blots of p-STAT3 in MiaPaCa-2 and S2-007 cells treated with vehicle or 3a (A19) at its IC 50 concentration for 24 h or 48 h; GAPDH served as a loading control. ( B ) Densitometric quantification of p-STAT3 (Tyr705) normalized to total STAT3, relative to the respective untreated control, for each cell line and time point. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by an unpaired two-tailed Student t -test versus the time-matched vehicle control.

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Compound 3a inhibited STAT3 phosphorylation (Tyr705) in PDAC cells. ( A ) Western blots of p-STAT3 in MiaPaCa-2 and S2-007 cells treated with vehicle or 3a (A19) at its IC 50 concentration for 24 h or 48 h; GAPDH served as a loading control. ( B ) Densitometric quantification of p-STAT3 (Tyr705) normalized to total STAT3, relative to the respective untreated control, for each cell line and time point. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by an unpaired two-tailed Student t -test versus the time-matched vehicle control.

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Phospho-proteomics, Western Blot, Concentration Assay, Control, Two Tailed Test

    Cellular thermal shift assay (CETSA) showing that 3a binds STAT3. ( A ) Representative Western blots of soluble STAT3 in MiaPaCa-2 cell lysates incubated with vehicle (DMSO) or 3a (A19) at 20 µM for 4 h, then heated at the indicated temperatures (44–68 °C) for 3 min. ( B ) Melting curves of soluble STAT3, quantified by densitometry and normalized to the 44 °C sample of each group. Curves were fitted by nonlinear (Boltzmann sigmoidal) regression. Derivative 3a raised the melting temperature (T m ) of STAT3 from 56.3 °C (vehicle) to 62.6 °C (ΔT m = +6.3 °C), indicating thermal stabilization of STAT3 by direct ligand binding. Data are presented as mean ± SD ( n = 3). p -values above individual temperatures compare vehicle with 3a at each temperature; the overall curve comparison (extra sum-of-squares F-test) gave p < 0.0001.

    Journal: International Journal of Molecular Sciences

    Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells

    doi: 10.3390/ijms272110013

    Figure Lengend Snippet: Cellular thermal shift assay (CETSA) showing that 3a binds STAT3. ( A ) Representative Western blots of soluble STAT3 in MiaPaCa-2 cell lysates incubated with vehicle (DMSO) or 3a (A19) at 20 µM for 4 h, then heated at the indicated temperatures (44–68 °C) for 3 min. ( B ) Melting curves of soluble STAT3, quantified by densitometry and normalized to the 44 °C sample of each group. Curves were fitted by nonlinear (Boltzmann sigmoidal) regression. Derivative 3a raised the melting temperature (T m ) of STAT3 from 56.3 °C (vehicle) to 62.6 °C (ΔT m = +6.3 °C), indicating thermal stabilization of STAT3 by direct ligand binding. Data are presented as mean ± SD ( n = 3). p -values above individual temperatures compare vehicle with 3a at each temperature; the overall curve comparison (extra sum-of-squares F-test) gave p < 0.0001.

    Article Snippet: The pancreatic cancer cell lines MiaPaCa-2 (ATCC CRL-1420), S2-007 (RRID: CVCL_B279; a clone of the SUIT-2 line originally established by Iwamura et al.) [ ], and Panc-1 (ATCC CRL-1469), and the human leukemia cell lines THP-1 (ATCC TIB-202) and Jurkat (clone E6-1, ATCC TIB-152) were provided as a gift by Dr. Shrikant Anant’s laboratory.

    Techniques: Thermal Shift Assay, Western Blot, Incubation, Ligand Binding Assay, Comparison

    ( a, b ) DHHC7 promotes pERK and 2-D cell growth of pancreatic cancer cells. ZDHHC7 was knockdown using siRNA in four mutant KRAS-driven pancreatic cancer cell lines (AsPC1, MiaPaca-2, PANC0327 and Tu8988s) ( a ) and one non-KRAS driven pancreatic cancer cell line (BxPC3) ( b ). pERK was measured using western blot and 2-D cell growth was measured using Cell Titer Glow after 48-72 hrs. ( c-d ) ZDHHC7 knockout affects pERK, 2-D cell growth, KRAS4A S-palmitoylation in MiaPaca-2 cell line. ZDHHC7 was CRISPR knockout and pERK levels ( c ) were detected using western blot and 2D cell growth was measured after 72 hrs. The endogenous S-acylation level of KRAS4A was detected using ABE ( d ). ( e ) ZDHHC7 was CRISPR knockout in AsPC1 cell line and pERK levels were detected using western blot. ( f-h ) ZDHHC7 knockout suppresses MiaPaca-2 xenograft tumor growth. Pancreatic cancer xerograph was performed using MiaPaca-2 cells with control or ZDHHC7 CRISPR knockout. The tumor volume was measured and quantified (f). The mice were dissected, and the final tumors were shown ( g ) and the tumor weights were quantified ( h ). ( i-k ) ZDHHC7 knockout suppresses AsPC1 xenograft tumor growth. ZDHHC7 CRISPR knockout was performed in AsPC1 cell line and similar xenograft experiment was performed. Tumor volume (i), tumors (j), tumor weight (k) are shown. Quantification data are shown as mean ± SD. ns, not significant. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Journal: bioRxiv

    Article Title: DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancers

    doi: 10.64898/2026.03.31.715686

    Figure Lengend Snippet: ( a, b ) DHHC7 promotes pERK and 2-D cell growth of pancreatic cancer cells. ZDHHC7 was knockdown using siRNA in four mutant KRAS-driven pancreatic cancer cell lines (AsPC1, MiaPaca-2, PANC0327 and Tu8988s) ( a ) and one non-KRAS driven pancreatic cancer cell line (BxPC3) ( b ). pERK was measured using western blot and 2-D cell growth was measured using Cell Titer Glow after 48-72 hrs. ( c-d ) ZDHHC7 knockout affects pERK, 2-D cell growth, KRAS4A S-palmitoylation in MiaPaca-2 cell line. ZDHHC7 was CRISPR knockout and pERK levels ( c ) were detected using western blot and 2D cell growth was measured after 72 hrs. The endogenous S-acylation level of KRAS4A was detected using ABE ( d ). ( e ) ZDHHC7 was CRISPR knockout in AsPC1 cell line and pERK levels were detected using western blot. ( f-h ) ZDHHC7 knockout suppresses MiaPaca-2 xenograft tumor growth. Pancreatic cancer xerograph was performed using MiaPaca-2 cells with control or ZDHHC7 CRISPR knockout. The tumor volume was measured and quantified (f). The mice were dissected, and the final tumors were shown ( g ) and the tumor weights were quantified ( h ). ( i-k ) ZDHHC7 knockout suppresses AsPC1 xenograft tumor growth. ZDHHC7 CRISPR knockout was performed in AsPC1 cell line and similar xenograft experiment was performed. Tumor volume (i), tumors (j), tumor weight (k) are shown. Quantification data are shown as mean ± SD. ns, not significant. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Article Snippet: Tumors were established by subcutaneously injecting MiaPaca-2 cells (3 × 10^6 cells per animal), PANC 0327 cells (1 x 10^6 cells per animal), AsPC1 cells (1 x 10^6 cells per animal) and BxPC3 cells (1 x 10^6 cells per animal) into 4- to 6-week-old male NSG mice (Jackson Laboratory, Bar Harbor, US).

    Techniques: Knockdown, Mutagenesis, Western Blot, Knock-Out, CRISPR, Control

    Cytotoxicity and Cell adsorption property of PVA-U varying G.D. (a) IC 50 values of MIAPaCa-2 cells treated with UDCA, PVA-U3, PVA-U15, and PVA-U25 for 24 h incubation at pH 7.4 and pH 6.5 (n = 3). (b) Cell viability of MIAPaCa-2 cells treated with 10 μg mL −1 PVA-U15 at pH 7.4 and pH 6.5 for 0, 4, 12, and 24 h incubation (n = 3). (c) Confocal images of MIAPaCa-2 cells treated with Cell tracker deep red and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 7.4 and pH 6.5 for 12 h incubation. Cell tracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 100 μm and 50 μm, respectively. Quantification of intracellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 24 h at pH 7.4 (d) and pH 6.5 (e) (n = 11). Quantification of pericellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 4 h at pH 7.4 (f) and pH 6.5 (g) (n = 11). (h) Confocal images of MIAPaCa-2 cells treated with lysotracker and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 6.5 for 4 h incubation. Lysotracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 50 μm and 10 μm, respectively. Statistical analysis was performed using unpaired two-tailed Student's t -test. Data are presented as mean ± S.D. ( N.S. : no significant difference, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001).

    Journal: Materials Today Bio

    Article Title: Escape from cell uptake: Drug-Free cancer therapeutics regulated by hydrophobicity and negative charge

    doi: 10.1016/j.mtbio.2025.102752

    Figure Lengend Snippet: Cytotoxicity and Cell adsorption property of PVA-U varying G.D. (a) IC 50 values of MIAPaCa-2 cells treated with UDCA, PVA-U3, PVA-U15, and PVA-U25 for 24 h incubation at pH 7.4 and pH 6.5 (n = 3). (b) Cell viability of MIAPaCa-2 cells treated with 10 μg mL −1 PVA-U15 at pH 7.4 and pH 6.5 for 0, 4, 12, and 24 h incubation (n = 3). (c) Confocal images of MIAPaCa-2 cells treated with Cell tracker deep red and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 7.4 and pH 6.5 for 12 h incubation. Cell tracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 100 μm and 50 μm, respectively. Quantification of intracellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 24 h at pH 7.4 (d) and pH 6.5 (e) (n = 11). Quantification of pericellular fluorescence intensity of MIAPaCa-2 cells treated with PVA-U0 (black), PVA-U3 (light blue), PVA-U15 (blue), and PVA-U25 (dark blue) incubated for 4 h at pH 7.4 (f) and pH 6.5 (g) (n = 11). (h) Confocal images of MIAPaCa-2 cells treated with lysotracker and 10 μg mL −1 PVA-U0-R, PVA-U3-R, PVA-U15-R, and PVA-U25-R at pH 6.5 for 4 h incubation. Lysotracker deep red and PVA-Us were shown in green and red color, respectively. Scale bars of images and enlarge images are 50 μm and 10 μm, respectively. Statistical analysis was performed using unpaired two-tailed Student's t -test. Data are presented as mean ± S.D. ( N.S. : no significant difference, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001).

    Article Snippet: MIAPaCa-2 cells, HT-29 cells, and A549 cells were purchased from the American Type Culture Collection (Manassas, VA, USA).

    Techniques: Adsorption, Incubation, Fluorescence, Two Tailed Test

    Antitumor efficacy of PVA-U15. (a) Treatment schedule for MIAPaCa-2 tumors. BALB/c nude mice were inoculated with MIAPaCa-2 cells on day 0. The tumor-bearing mice were randomized and treated with UDCA (144 μM), PVA (10 μg mL −1 ) or PVA-U15 (10 μg mL −1 ). 100 μL of each solution was intratumorally injected 5 days per week from day 9 to day 21. (b) Tumor growth in mice treated with PVA (black), UDCA (blue), and PVA-U15 (red). (c) Body weight of mice treated with PVA (black), UDCA (blue), and PVA-U15 (red). Statistical analysis was performed using Tukey test. Data are presented as mean ± S.D. (∗ p < 0.05).

    Journal: Materials Today Bio

    Article Title: Escape from cell uptake: Drug-Free cancer therapeutics regulated by hydrophobicity and negative charge

    doi: 10.1016/j.mtbio.2025.102752

    Figure Lengend Snippet: Antitumor efficacy of PVA-U15. (a) Treatment schedule for MIAPaCa-2 tumors. BALB/c nude mice were inoculated with MIAPaCa-2 cells on day 0. The tumor-bearing mice were randomized and treated with UDCA (144 μM), PVA (10 μg mL −1 ) or PVA-U15 (10 μg mL −1 ). 100 μL of each solution was intratumorally injected 5 days per week from day 9 to day 21. (b) Tumor growth in mice treated with PVA (black), UDCA (blue), and PVA-U15 (red). (c) Body weight of mice treated with PVA (black), UDCA (blue), and PVA-U15 (red). Statistical analysis was performed using Tukey test. Data are presented as mean ± S.D. (∗ p < 0.05).

    Article Snippet: MIAPaCa-2 cells, HT-29 cells, and A549 cells were purchased from the American Type Culture Collection (Manassas, VA, USA).

    Techniques: Injection

    TNFAIP8 is enriched in insulin‐stimulated PDAC exosomes and promotes CAF activation. (A) Heatmap of differentially expressed proteins in exosomes from insulin‐treated versus control MIA PaCa‐2 cells. (B) KEGG pathway enrichment analysis of upregulated exosomal proteins. (C) Expression of TNFAIP8 based on normalized TCGA‐PAAD data. (D) Forest plot summarizing Cox regression analyses linking TNFAIP8 expression to survival outcomes across multiple datasets (TCGA, GSE79668 , GSE28735 , GSE57495 , ICGC, GSE62452 , GSE85916 , MTAB_6134, GSE71729 , GSE21501 ). (E) Kaplan‐Meier survival analyses for TNFAIP8 expression in PDAC cohorts. (TCGA, GSE85916 , GSE57495 ). Data were analyzed using the BEST (Biomarker Evaluation & Survival Tool) database (D, E). (F) IF images showing uptake of exosomes by CAFs. Scale bars, 20 µm. (G) ELISA quantification of TNFAIP8 levels in cell supernatants and exosomes from indicated PDAC cells (MIAPaCa‐2, PANC1) ( n = 3 biological replicates). (H) ELISA measurement of TNFAIP8 concentration in CM and exosome fractions collected from MIA PaCa‐2 cells under control or insulin treatment, with sh‐NC or sh‐TNFAIP8 expression. ( n = 3 biological replicates). (I) CCK‐8 assay for CAF viability after exosome or rTNFAIP8 treatment ( n = 3 biological replicates). (J) Representative EdU staining images and quantification of CAF proliferation under indicated treatments ( n = 5 biological replicates). Scale bars, 50 µm. (K) 3D fluorescence intensity plots showing α‐SMA and COL1A1 expression in CAFs under indicated treatments. (L) Multiplex IF staining of human PDAC tissues showing co‐localization of TNFAIP8 with α‐SMA and CK19, Samples include normal pancreas, Tumor‐INS‐Low, and Tumor‐INS‐High groups. The Tumor‐INS‐High group consists of PDAC patients with elevated insulin levels in both tumor tissue and matched fasting serum, whereas Tumor‐INS‐Low represents patients with lower insulin levels. (TMA, n = 60; Tumor‐INS‐High, n = 15; Tumor‐INS‐Low, n = 45). Scale bars: 500 and 50 µm. (M) Correlation analyses between TNFAIP8 expression and stromal markers (ACTA2 and COL1A1) in TCGA PDAC samples. Statistical comparisons between two groups were performed using a two‐tailed unpaired Student's t ‐tests (C). Data in (G, H, I, J) are shown as mean ± SD, analyzed by one‐way ANOVA with Tukey's test; Significance thresholds: ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Advanced Science

    Article Title: An Insulin‐Exosome‐TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer

    doi: 10.1002/advs.202515606

    Figure Lengend Snippet: TNFAIP8 is enriched in insulin‐stimulated PDAC exosomes and promotes CAF activation. (A) Heatmap of differentially expressed proteins in exosomes from insulin‐treated versus control MIA PaCa‐2 cells. (B) KEGG pathway enrichment analysis of upregulated exosomal proteins. (C) Expression of TNFAIP8 based on normalized TCGA‐PAAD data. (D) Forest plot summarizing Cox regression analyses linking TNFAIP8 expression to survival outcomes across multiple datasets (TCGA, GSE79668 , GSE28735 , GSE57495 , ICGC, GSE62452 , GSE85916 , MTAB_6134, GSE71729 , GSE21501 ). (E) Kaplan‐Meier survival analyses for TNFAIP8 expression in PDAC cohorts. (TCGA, GSE85916 , GSE57495 ). Data were analyzed using the BEST (Biomarker Evaluation & Survival Tool) database (D, E). (F) IF images showing uptake of exosomes by CAFs. Scale bars, 20 µm. (G) ELISA quantification of TNFAIP8 levels in cell supernatants and exosomes from indicated PDAC cells (MIAPaCa‐2, PANC1) ( n = 3 biological replicates). (H) ELISA measurement of TNFAIP8 concentration in CM and exosome fractions collected from MIA PaCa‐2 cells under control or insulin treatment, with sh‐NC or sh‐TNFAIP8 expression. ( n = 3 biological replicates). (I) CCK‐8 assay for CAF viability after exosome or rTNFAIP8 treatment ( n = 3 biological replicates). (J) Representative EdU staining images and quantification of CAF proliferation under indicated treatments ( n = 5 biological replicates). Scale bars, 50 µm. (K) 3D fluorescence intensity plots showing α‐SMA and COL1A1 expression in CAFs under indicated treatments. (L) Multiplex IF staining of human PDAC tissues showing co‐localization of TNFAIP8 with α‐SMA and CK19, Samples include normal pancreas, Tumor‐INS‐Low, and Tumor‐INS‐High groups. The Tumor‐INS‐High group consists of PDAC patients with elevated insulin levels in both tumor tissue and matched fasting serum, whereas Tumor‐INS‐Low represents patients with lower insulin levels. (TMA, n = 60; Tumor‐INS‐High, n = 15; Tumor‐INS‐Low, n = 45). Scale bars: 500 and 50 µm. (M) Correlation analyses between TNFAIP8 expression and stromal markers (ACTA2 and COL1A1) in TCGA PDAC samples. Statistical comparisons between two groups were performed using a two‐tailed unpaired Student's t ‐tests (C). Data in (G, H, I, J) are shown as mean ± SD, analyzed by one‐way ANOVA with Tukey's test; Significance thresholds: ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: The proliferation of PANC‐1 and MiaPaca‐2 cells was studied using the cell counting kit‐8 (CCK‐8, Dojindo, Japan) and 5‐ethynyl‐2′‐deoxyuridine assay (EdU, Beyotime, China) assays, as described in our previous studies [ ].

    Techniques: Activation Assay, Control, Expressing, Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Concentration Assay, CCK-8 Assay, Staining, Fluorescence, Multiplex Assay, Two Tailed Test

    Glycolytic Profiling and LDHA Inhibition Reveal Differential Sensitivity Across PDAC Cell Lines. a Heatmap of glycolytic signature expression, reported as normalized transcript per million (nTPM) across five PDAC cell lines from Human Protein Atlas. b Western blot analysis of LDHA expression in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells. c Glycolytic activity in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells after LDHA-i treatment, measured as extracellular acidification rate (ECAR). Each dot represents a biological replicate ( n = 6 per group). Data are represented as mean ± SD. Statistical analysis performed with a paired t -test. d Viability assay in MIAPaCa-2 (green), PANC-1 (blue), PL45 (purple), HPAF-II (red), and HPDE6c7 (brown) cells upon LDHA-i treatment at 24 and 48 h. Boxplots display IC50 values for each time point across cell lines, with statistical significance assessed by paired t -test ( n = 2 per group). On the right, GR50 and GRmax values represent drug potency and efficacy, respectively

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma

    doi: 10.1038/s41392-025-02546-8

    Figure Lengend Snippet: Glycolytic Profiling and LDHA Inhibition Reveal Differential Sensitivity Across PDAC Cell Lines. a Heatmap of glycolytic signature expression, reported as normalized transcript per million (nTPM) across five PDAC cell lines from Human Protein Atlas. b Western blot analysis of LDHA expression in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells. c Glycolytic activity in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells after LDHA-i treatment, measured as extracellular acidification rate (ECAR). Each dot represents a biological replicate ( n = 6 per group). Data are represented as mean ± SD. Statistical analysis performed with a paired t -test. d Viability assay in MIAPaCa-2 (green), PANC-1 (blue), PL45 (purple), HPAF-II (red), and HPDE6c7 (brown) cells upon LDHA-i treatment at 24 and 48 h. Boxplots display IC50 values for each time point across cell lines, with statistical significance assessed by paired t -test ( n = 2 per group). On the right, GR50 and GRmax values represent drug potency and efficacy, respectively

    Article Snippet: The PL45 (CRL-2558), SW1990 (CRL-2172), PANC-1 (CRL-1469), HPAF-II (CRL-1997), and MIAPaCa-2 (CRL-1420) cell lines were purchased from ATCC.

    Techniques: Inhibition, Expressing, Western Blot, Activity Assay, Viability Assay

    Metabolomic, Proteomic, and Transcriptomic Profiling Uncovers the Impact of LDHA Inhibition in PDAC. a Amount of lactate in MIAPaCa-2 and PL45 cells at the basal level (gray) and after LDHA inhibition (blue). Each dot represents a biological replicate ( n = 6 per group). Data are shown as normalized intensity and are represented as mean ± SD. Statistical significance was calculated with a paired t -test. b Pathway enrichment analysis performed on metabolomics data in MIAPaCa-2 cells at basal level and after LDHA inhibition. The x -axis indicates pathway impact based on metabolite expression. The y -axis indicates p value transformed as −Log 10 . c Significant results from enrichment analysis performed on proteomics data in MIAPaCa-2 cells after LDHA inhibition. The x -axis indicates the normalized enrichment score. The label shows p value transformed as −Log 10 . d Enrichment plots for glycolysis and hypoxia in MIAPaCa-2 cells treated with LDHA-i. Normalized enrichment score and p value are reported in the figure. e Hallmarks significantly upregulated in PDAC patient samples exhibiting High glycolytic profile compared to those with Low glycolytic profile (left). Hallmarks significantly downregulated in MIAPaCa-2 cells following treatment with LDHA-i (right). The y -axis indicates the normalized enrichment score

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma

    doi: 10.1038/s41392-025-02546-8

    Figure Lengend Snippet: Metabolomic, Proteomic, and Transcriptomic Profiling Uncovers the Impact of LDHA Inhibition in PDAC. a Amount of lactate in MIAPaCa-2 and PL45 cells at the basal level (gray) and after LDHA inhibition (blue). Each dot represents a biological replicate ( n = 6 per group). Data are shown as normalized intensity and are represented as mean ± SD. Statistical significance was calculated with a paired t -test. b Pathway enrichment analysis performed on metabolomics data in MIAPaCa-2 cells at basal level and after LDHA inhibition. The x -axis indicates pathway impact based on metabolite expression. The y -axis indicates p value transformed as −Log 10 . c Significant results from enrichment analysis performed on proteomics data in MIAPaCa-2 cells after LDHA inhibition. The x -axis indicates the normalized enrichment score. The label shows p value transformed as −Log 10 . d Enrichment plots for glycolysis and hypoxia in MIAPaCa-2 cells treated with LDHA-i. Normalized enrichment score and p value are reported in the figure. e Hallmarks significantly upregulated in PDAC patient samples exhibiting High glycolytic profile compared to those with Low glycolytic profile (left). Hallmarks significantly downregulated in MIAPaCa-2 cells following treatment with LDHA-i (right). The y -axis indicates the normalized enrichment score

    Article Snippet: The PL45 (CRL-2558), SW1990 (CRL-2172), PANC-1 (CRL-1469), HPAF-II (CRL-1997), and MIAPaCa-2 (CRL-1420) cell lines were purchased from ATCC.

    Techniques: Metabolomic, Inhibition, Expressing, Transformation Assay

    Integrative multiomics analysis correlates molecular signatures in PDAC. a Clustered image map of variables selected by multiblock partial least squares discriminant analysis (PLS-DA) based on omics datasets. Samples are displayed as rows, and selected features in columns. Histograms represent significant functional analysis results for proteins (light green), pathway analysis for metabolites (red), and enrichment analysis for lipids (purple). Statistical significance is expressed as −Log 10 transformed p values. b Circos plot from multiblock PLS-DA performed on proteomic (green), metabolomic (red), and lipidomic (purple) data in MIAPaCa-2 cells treated with LDHA-i. The plot shows correlations between 0.7 and −0.7 across proteins, metabolites, and lipids, represented on the side quadrants. The internal connecting lines show positive (light brown) and negative (black) correlations. c Network plot of correlated features derived by multiblock PLS-DA. Each node represents a variable, color-coded by type. The color of the edges indicates positive (light brown) or negative (black) correlations greater than ±0.7 between variables of different types

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma

    doi: 10.1038/s41392-025-02546-8

    Figure Lengend Snippet: Integrative multiomics analysis correlates molecular signatures in PDAC. a Clustered image map of variables selected by multiblock partial least squares discriminant analysis (PLS-DA) based on omics datasets. Samples are displayed as rows, and selected features in columns. Histograms represent significant functional analysis results for proteins (light green), pathway analysis for metabolites (red), and enrichment analysis for lipids (purple). Statistical significance is expressed as −Log 10 transformed p values. b Circos plot from multiblock PLS-DA performed on proteomic (green), metabolomic (red), and lipidomic (purple) data in MIAPaCa-2 cells treated with LDHA-i. The plot shows correlations between 0.7 and −0.7 across proteins, metabolites, and lipids, represented on the side quadrants. The internal connecting lines show positive (light brown) and negative (black) correlations. c Network plot of correlated features derived by multiblock PLS-DA. Each node represents a variable, color-coded by type. The color of the edges indicates positive (light brown) or negative (black) correlations greater than ±0.7 between variables of different types

    Article Snippet: The PL45 (CRL-2558), SW1990 (CRL-2172), PANC-1 (CRL-1469), HPAF-II (CRL-1997), and MIAPaCa-2 (CRL-1420) cell lines were purchased from ATCC.

    Techniques: Functional Assay, Transformation Assay, Metabolomic, Derivative Assay